Search results
Showing 1451 to 1500 of 2026 results for work
Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]
Discontinued Reference number: GID-TA10065
U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)
NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .
NICE has developed a medtech innovation briefing (MIB) on URO17 for detecting bladder cancer .
UroShield for preventing catheter-associated urinary tract infections (HTG620)
Evidence-based recommendations on UroShield for preventing catheter-associated urinary tract infections.
Evidence-based recommendations on iFuse for treating chronic sacroiliac joint pain.
Peristeen Plus transanal irrigation system for managing bowel dysfunction (HTG462)
Evidence-based recommendations on Peristeen Plus transanal irrigation system for managing bowel dysfunction.
This guide gives an overview of the process for developing evidence summaries. Evidence summaries provide advice but do not include recommendations and are not formal NICE guidance
Cardiovascular disease. Patient decision aid on should I take a statin?
statin involve? You would need to take a statin tablet every day for it to work. You would usually keep taking it long term (for many...
Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
Discontinued Reference number: GID-QS10108
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)
Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected stage 2B and 2C melanoma in people 12 years and over.
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)
Evidence-based recommendations on budesonide as an orodispersible tablet for inducing remission of eosinophilic oesophagitis in adults.
Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.
View recommendations for TA223Show all sections
Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults.
Omalizumab for treating severe persistent allergic asthma (TA278)
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.
Evidence-based recommendations on durvalumab (Imfinzi) with tremelimumab (Imjudo) for untreated advanced or unresectable hepatocellular carcinoma in adults.
Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)
Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults.
A new aligned pathway between NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) will help bring medicines to patients faster.
Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.
Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for transfusion-dependent beta-thalassaemia in people 12 years and over.
Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)
Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C.
Digital technologies to support self-management of COPD: early value assessment (HTG736)
Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]
Discontinued Reference number: GID-HST10007
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]
Discontinued Reference number: GID-TA10377
This guideline covers identifying and caring for adults who are malnourished or at risk of malnutrition in hospital or in their own home or a care home. It offers advice on how oral, enteral tube feeding and parenteral nutrition support should be started, administered and stopped. It aims to support healthcare professionals identify malnourished people and help them to choose the most appropriate form of support.
NICE has developed a medtech innovation briefing (MIB) on AlignRT in breast cancer radiotherapy .
Health inequalities can be experienced by people grouped by a range of different factors.
Adrenal insufficiency: identification and management (NG243)
This guideline covers identifying and managing adrenal insufficiency (hypoadrenalism) in babies, children, young people and adults. It aims to improve the treatment of primary, secondary and tertiary adrenal insufficiency, and the prevention and management of adrenal crisis.
Discontinued Reference number: GID-TA10739
Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)
Discontinued Reference number: GID-TA10527
Discontinued Reference number: GID-IP1156
Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.
Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)
Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.
Show all sections
Dasatinib for the treatment of acute lymphoblastic leukaemia [ID386]
Discontinued Reference number: GID-TAG399
In development Reference number: GID-QS10176 Expected publication date: TBC
Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)
Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]
In development Reference number: GID-TA10900 Expected publication date: TBC
Discontinued Reference number: GID-TA10202
Discontinued Reference number: GID-TA10271
Discontinued Reference number: GID-TA10566
Discontinued Reference number: GID-TA11207
Discontinued Reference number: GID-TA11206
Masitinib for previously treated moderate Crohn's disease [ID1239]
Discontinued Reference number: GID-TA11188
Multiple myeloma (untreated) - carfilzomib (with melphalan and prednisone) [ID1133]
Discontinued Reference number: GID-TA11210
Ovarian (epithelial), fallopian, peritoneal cancer - paclitaxel (encapsulated in XR-17 [ID565]
Discontinued Reference number: GID-TA11209
In development Reference number: GID-TA11689 Expected publication date: TBC
This quality standard covers prevention of falls and assessment after a fall in people who are living in the community, in a residential care setting or staying in hospital and are:
View quality statements for QS86Show all sections
Sections for QS86
- Quality statements
- Quality statement 1: Asking people about falls
- Quality statement 2: Comprehensive falls assessment
- Quality statement 3: Interventions to reduce the risk of falls
- Quality statement 4: Checks for injury after an inpatient fall
- Quality statement 5: Safe manual handling after an inpatient fall
- Quality statement 6: Medical examination after an inpatient fall
- Quality statement 7: Multifactorial risk assessment for older people presenting for medical attention
Cardiovascular events (prevention, high risk) - anacetrapib [ID1164]
Discontinued Reference number: GID-TA11176
Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID977]
Discontinued Reference number: GID-TA11238
Hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea (HTG455)
Evidence-based recommendations on hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea in adults. This involves implanting a device under the skin in the chest and connecting it to a nerve under the tongue (hypoglossal nerve).